MedTrace Logo

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

NCT06893887 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-07-02

No results posted yet for this study

Summary

This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy. Based on different patterns of disease progression, patients will receive relevant systemic treatments, either with or without local interventional therapy. The primary endpoint is progression-free survival (PFS), while secondary endpoints include overall survival (OS), 1-year OS rate, objective response rate (ORR), disease control rate (DCR), duration of remission (DOR), and safety. Additionally, the study will explore the correlation between patients' clinical pathological characteristics, serum biomarkers, and clinical efficacy.

Conditions

  • Hepatocellular Carcinoma(HCC)

Interventions

DRUG

FOLFOX4

FOLFOX4 was administered by oxaliplatin 85 mg/m² d1+ leucovorin 200 mg/m² d1-2+ fluorouracil 400 mg/m² 2 h→ 600 mg/m² 24 h d1-2 q2w, with a total of 4 cycles

DRUG

Adebrelimab

Adebrelimab 1200mg, intravenous infusion, every 3 weeks

DRUG

Apatinib

Apatinib 250mg, oral, once daily.

DRUG

Icaritin

Epimedium extract soft capsules 2.4g, oral, 2 times daily.

DRUG

SHR-1701

SHR1701，30mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

DRUG

QL1706

QL1706，5mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.

DRUG

Bevacizumab

Bevacizumab 7.5mg, intravenous infusion, once every 3 weeks.

PROCEDURE

HAIC

Hepatic Arterial Infusion Chemotherapy

PROCEDURE

Local treatment

Local treatment of oligo-metastases.

DRUG

The original treatment regimen

Continue the original targeted therapy combined with immunotherapy. dosage, dosage form,frequency of administration was the same as before.

Sponsors & Collaborators

  • Nanjing Tianyinshan Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2027-03-15
Completion
2028-03-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06893887 on ClinicalTrials.gov